Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation

BACKGROUND: Chemoresistance is an obstacle to the successful treatment of nasopharyngeal carcinoma (NPC). Lapatinib is a targeted tyrosine kinase inhibitor therapeutic drug also used to treat NPC, but high doses are often required to achieve a result. To investigate the mechanism for the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Aimjongjun, Sathid, Mahmud, Zimam, Jiramongkol, Yannasittha, Alasiri, Glowi, Yao, Shang, Yagüe, Ernesto, Janvilisri, Tavan, Lam, Eric W.-F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854897/
https://www.ncbi.nlm.nih.gov/pubmed/31727006
http://dx.doi.org/10.1186/s12885-019-6308-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854897/
https://www.ncbi.nlm.nih.gov/pubmed/31727006
http://dx.doi.org/10.1186/s12885-019-6308-7

Ejemplares similares